Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $17.71 Average PT from Brokerages

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRVGet Free Report) have earned a consensus rating of “Buy” from the ten brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $17.71.

A number of equities research analysts have recently issued reports on ACRV shares. Oppenheimer lowered their price target on shares of Acrivon Therapeutics from $10.00 to $9.00 and set an “outperform” rating on the stock in a report on Thursday, May 15th. HC Wainwright decreased their target price on shares of Acrivon Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. Piper Sandler initiated coverage on shares of Acrivon Therapeutics in a research note on Monday, May 5th. They issued an “overweight” rating and a $6.00 target price on the stock. Jones Trading reissued a “hold” rating on shares of Acrivon Therapeutics in a report on Friday, May 16th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Acrivon Therapeutics in a research report on Wednesday, March 26th.

Get Our Latest Research Report on ACRV

Insider Buying and Selling

In other news, major shareholder Perceptive Advisors Llc sold 215,283 shares of the firm’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $1.56, for a total transaction of $335,841.48. Following the sale, the insider now owns 4,090,906 shares in the company, valued at approximately $6,381,813.36. This trade represents a 5.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 1,707,833 shares of company stock worth $3,009,858. Insiders own 8.50% of the company’s stock.

Institutional Trading of Acrivon Therapeutics

Hedge funds have recently made changes to their positions in the stock. Northern Trust Corp increased its stake in Acrivon Therapeutics by 11.3% in the fourth quarter. Northern Trust Corp now owns 117,323 shares of the company’s stock valued at $706,000 after acquiring an additional 11,925 shares during the last quarter. Acorn Capital Advisors LLC purchased a new position in shares of Acrivon Therapeutics during the fourth quarter worth approximately $2,440,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Acrivon Therapeutics by 29.7% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock worth $619,000 after acquiring an additional 23,535 shares in the last quarter. Corton Capital Inc. bought a new stake in shares of Acrivon Therapeutics in the 4th quarter worth approximately $73,000. Finally, Wealthedge Investment Advisors LLC purchased a new stake in shares of Acrivon Therapeutics in the 4th quarter valued at $65,000. 71.62% of the stock is owned by institutional investors.

Acrivon Therapeutics Price Performance

Acrivon Therapeutics stock opened at $1.18 on Thursday. The firm has a market capitalization of $36.99 million, a P/E ratio of -0.53 and a beta of 1.56. Acrivon Therapeutics has a one year low of $1.05 and a one year high of $10.16. The business has a fifty day moving average price of $1.35 and a 200-day moving average price of $3.80.

Acrivon Therapeutics (NASDAQ:ACRVGet Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.06. Sell-side analysts expect that Acrivon Therapeutics will post -2.49 earnings per share for the current fiscal year.

Acrivon Therapeutics Company Profile

(Get Free Report

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Recommended Stories

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.